# Pluslife

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pluslife

- Industry: Medical Devices & Equipment
- Headquarters: Guangzhou, China
- Website: www.pluslife.com
- Latest round: Series A (Nov 17, 2025)
- Investors on record: 3

## About

Based in Guangzhou, China and founded in 2017, Guangzhou Pushilihua Technology Co., Ltd, trading as Pluslife, developing innovative molecular diagnostic products using next-generation gene technologies, providing complete solutions from core protein research and development, molecular detection methodology development, to molecular point-of-care testing (POCT) products. In November 2025, Pluslife closed a Series A+ funding from new investors FC Innovation Venture Fund, Puhua Capital and Guangzhou Guoju Venture Capital.
The company specializes in advanced diagnostic solutions through its proprietary RNase Hybridization Assisted Amplification (RHAM) technology, which provides high sensitivity and specificity comparable to laboratory PCR tests. Its flagship products, the MiniDock and Dock Pro 8, are designed for accuracy akin to quantitative PCR (qPCR) while maintaining user-friendliness similar to rapid diagnostic tests (RDTs). These products are aimed at addressing various infectious diseases, including tuberculosis and sexually transmitted infections, and serve clinical, point-of-care, and public health settings, particularly in regions like Nigeria and other developing nations.
The company generates revenue primarily through direct sales of its diagnostic products, including the MiniDock and Dock Pro 8, targeting healthcare providers, laboratories, and public health initiatives. The company has established partnerships with organizations such as the Gates Foundation to enhance distribution and recognition in public health procurement systems. Revenue is bolstered through bulk orders from healthcare institutions and government agencies seeking effective diagnostic solutions.
The Series A+ funding raised in November 2025 will be used by the company to drive innovation and application of molecular diagnostic technology, injecting new momentum into the field of precision medicine.

## Funding rounds

- Series A, Nov 17, 2025 — Puhua Capital, Guangzhou Guoju Venture Capital, FC Innovation Venture Fund

## Investors

- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A
- Guangzhou Guoju Venture Capital (https://capitalatlas.ai/funds/guangzhou-guoju-venture-capital) — Series A
- FC Innovation Venture Fund (https://capitalatlas.ai/funds/fc-innovation-venture-fund) — Series A